Restart Life Sciences Corp. (CNSX: HEAL)
Health Care · Biotechnology · CA
CA$0.07
— today · -12.5% 1Y
Restart Life Sciences Corp. (CNSX: HEAL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.15M and employs 3 people.
Over the last twelve months the share price has lost 12.5%, trading between 0.07 and 0.14.
Tweenvest scores Restart Life Sciences Corp. across four factors: quality 37/100, value 63/100. Its strongest factor is value.
HEAL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.15M
- Revenue (TTM)
- $96.39K
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- -0.76
- 52-week high
- CA$0.14
- 52-week low
- CA$0.07
- Avg volume (3M)
- —
- Shares outstanding
- 62.36M
- Employees
- 3
- Next earnings
- —
About Restart Life Sciences Corp.
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
- ISIN
- CA76134J2065
- Founded
- 2004
- Listed since
- Sep 22, 2006
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.96 | +0.06% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.51 | -0.83% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.